key: cord-0995937-kofzkv8w
authors: Argyropoulos, Kimon V.; Serrano, Antonio; Hu, Jiyuan; Black, Margaret; Feng, Xiaojun; Shen, Guomiao; Call, Melissa; Kim, Min Jae; Lytle, Andrew; Belovarac, Brendan; Vougiouklakis, Theodore; Lin, Lawrence Hsu; Moran, Una; Heguy, Adriana; Troxel, Andrea; Snuderl, Matija; Osman, Iman; Cotzia, Paolo; Jour, George
title: ASSOCIATION OF INITIAL VIRAL LOAD IN SARS-CoV-2 PATIENTS WITH OUTCOME AND SYMPTOMS
date: 2020-07-03
journal: Am J Pathol
DOI: 10.1016/j.ajpath.2020.07.001
sha: 4049173c7dd1c8121691f00e02a8ef30957bcef0
doc_id: 995937
cord_uid: kofzkv8w

The dynamics of viral load (VL) of the 2019 novel coronavirus (SARS-CoV-2) and its association with different clinical parameters remain poorly characterized in the United States patient population. Herein we investigate associations between VL and parameters such as severity of symptoms, disposition (admission vs direct discharge), length of hospitalization, and admission to the intensive care unit, length of need for oxygen support and overall survival in a cohort of 205 patients from a tertiary care center in New York City. VL was determined using q-PCR and Log10 transformed for normalization. Univariate and multivariate regression models were used to test these associations. We found that diagnostic viral load is significantly lower in hospitalized patients than in patients not hospitalized (log10 VL = 3.3 vs.4.0; p=0.018) after adjusting for age, sex, race, BMI, and comorbidities. Higher VL was associated with shorter duration of the symptoms in all patients and hospitalized patients only and shorter hospital stay (coefficient =-2.02,-2.61, -2.18; p<0.001, p=0.002, p=0.013, respectively). No significant association was noted between VL, admission to ICU, length of oxygen support, and overall survival. Our findings suggest a higher shedding risk in less symptomatic patients; an important consideration for containment strategies in SARS-CoV-2. Furthermore, we identify a novel association between viral load and history of cancer. Larger studies are warranted to validate our findings.

The 2019 novel coronavirus (SARS-CoV-2), was first documented in December 2019 in Wuhan, China, and has resulted thus far in significant global morbidity and mortality 1 . SARS-CoV-2 is genetically related to SARS-CoV, which caused an epidemic in 2002-2003. Though not proven, it is believed that the epidemic of SARS-CoV was successfully contained through public health interventions, nonetheless besides differences in policy timeliness and effectiveness between the two epidemics, SARS-CoV-2 has proven to be significantly more difficult to contain. Both viruses utilize the same receptor for cell entry, however SARS-COV-2 uses a modified spike protein, which has a higher avidity for the corresponding human receptor and likely amplifies viral infectivity 2, 3 . Moreover, the two viruses appear to have different shedding kinetics.

SARS-CoV viral load peaks on average 10 days after symptom onset; in comparison a recent study with 94 subjects from the Guangzhou Eighth People's Hospital in China showed that SARS-CoV-2 viral load peaks at 0.7 days before symptom onset, suggesting that transmission occurs early in the course of the infection [4] [5] [6] [7] . As a result, disease containment may require strategies different from those utilized in the containment of SARS-CoV. Additionally, authors compared viral load kinetics in mild and severe cases of COVID-19 and reported no differences between the two groups 7 .

In a similar fashion ,a study with 5000 subjects from Lombardy, Italy, showed no difference in viral loads between asymptomatic carriers and symptomatic COVID-19 patients 8 . On the other hand, a study with 76 patients in Nanchang, China showed that hospitalized patients with severe disease tend to have a high viral load and a longer virus-shedding period compared to milder cases 9 .

Up to date, there are no studies investigating association between viral load with different clinical parameters and outcome in the United States' patient population. Here in, we sought to identify potential associations between viral load obtained from SARS CoV-2 positive patients at the emergency department in tertiary care center in the New York City and its association with different clinical parameters. These parameters included severity of symptoms, disposition (admission vs direct discharge), length of hospitalization, admission to the intensive care unit, length of need for oxygen support and overall survival. We also sought to address whether certain comorbidities are associated with a higher viral load or not.

After review and approval (study # i20-00616) by the institutional Board, we conducted a retrospective observational study, to include patients with confirmed COVID-19 that presented to our emergency department in Manhattan, NY, USA between March 12th to 18th, 2020. Only adult patients (>18 years old) are included in this study. Clinical and demographic data were collected by the Center for Biospecimen Research and Development at NYU under an approved IRB protocol (study # S16-00122) Universal

Mechanism of human bio-specimen collection and storage for research 10 . Patient data was collected from the electronic medical record and we analyzed baseline demographics, severity of symptoms, therapeutic management, clinical course, laboratory data and clinical outcomes. Duration of symptoms was calculated from the day of onset to the collection of the nasopharyngeal swab. Analysis of certain comorbidities such as hypertension, asthma, chronic obstructive pulmonary disease (COPD), diabetes, chronic kidney disease (CKD) and cancer history were included.

Follow up duration was 8 weeks.

Nasopharyngeal swabs were collected from all patients presenting to our emergency department with suspected Covid-19 infection. Collection of the nasopharyngeal sample was performed by trained medical personnel. The nasopharyngeal samples were transferred to viral transport media immediately after collection and transported to microbiology and molecular pathology for further testing. A total of 205 sequential patients without any exclusions were tested using both qualitative RT-PCR and quantitative RT-PCR to obtain diagnostic SARS-CoV-2 viral load (CDC kit which was submitted for FDA review under emergency authorization utilization on 03/24/2020) at initial presentation. 

We performed descriptive analyses of the baseline characteristics and clinical parameters in frequencies and proportions for categorical variables, and medians and interquartile ranges (IQR) for continuous variables respectively. Wilcoxon Rank Sum test (two-sided) and Pearson's Chi-squared test were used to assess the difference between hospitalized and non-hospitalized patients for continuous and categorical baseline characteristics respectively. Fisher's exact test was used instead for analyzing categorical variables when one or more of the observed cell counts were less than 5.

Viral load was log 10 transformed for normalization prior to analysis. The association between VL upon admission and clinical parameters was assessed among all patients and patients that were hospitalized respectively. Specifically, simple linear regression of continuous clinical parameters against the viral load was fitted to the data to assess the association between VL and clinical parameters. Logistic regression for dichotomous clinical parameters against the viral load was fitted to the data to assess the association between VL and clinical parameters. The associations were further assessed with regression models adjusting for age, sex, race, BMI, and comorbidities. The effect sizes of association were shown as regression coefficients and 95% confidence intervals (CIs) for continuous parameters, and odds ratios and 95% CIs for dichotomous parameters respectively. Analyses were performed using R version 3.6.1. P-value <0.05 was indicated as statistically significant and p-value <0.10 was indicated as marginally significant.

Two hundred and five (205) patients were included in the study including 165 discharged patients from the ED and 40 hospitalized patients. Non-hospitalized patients were overall younger (median age: 45 years old) compared to hospitalized patients (median age: 60 years old, p<0.001). Other baseline characteristics, including sex, race, body mass index (BMI) and comorbidities showed no statistically significant difference in terms of distribution between the two groups ( Table 1 ). The group of hospitalized patients was expectedly enriched in patients with severe or critical COVID-19 (p<0.001) ( Table 2 ). The median duration of symptoms from symptom onset to nasopharyngeal swab collection in that group was 5 days as opposed to 3 days in the non-hospitalized group (p=0.017) . Median hospitalization duration was 6.5 days (Table   2 ).

Diagnostic viral load titers were significantly lower in patients that ended up being admitted compared to patients who did not (log10 VL = 3.3 vs.4.0, p=0.014) ( Figure 1 , Table 2 ). Multivariate linear regression analysis corroborated these findings showing that this association is independent of the effect of other confounders including age, sex, race, comorbidities, and BMI (p=0.018, Table 2 , footnote).

Univariate analysis showed an inverse correlation between duration of symptoms and viral load (p<0.001, p= 0.005) in all enrolled patients and hospitalized patients respectively (Table 3) . A similar inverse correlation was noted between length of hospitalization and viral load in hospitalized patients (p=0.013, Table 3 ). Multivariate analysis adjusting for age, sex, race, BMI and comorbidities corroborated these findings showing a significant inverse correlation between viral load and the duration of symptoms (p<0.001, p=0.008) and a trend with length of hospitalization (p=0.078) ( Table 4 ). As noted above, higher viral loads also showed an inverse correlation with COVID severity across the cohort and in the subgroup of hospitalized patients, which marginally did not meet statistical significance in a univariate analysis (p=0.056, p=0.097, Table 3 ), but was statistically significant in the hospitalized group after adjusting for age, sex, race, BMI, and comorbidities (p=0.045, Table 4 ). A total of 14 patients [Thirty-five percent (35%) of the hospitalized patients, 7% of the whole cohort] were admitted to the intensive care unit ICU and eight of them (22.5%) died (Table 2) . Viral load showed no statistically significant correlation with duration of oxygen support, admission to ICU or mortality (Tables 3 and 4) . Assessment of the relationship of the diagnostic viral load with separate comorbidities in all enrolled patients showed a significant positive correlation with a history of cancer (p = 0.033, Table 5 ) and cardiovascular disorders (such as coronary artery disease, arrhythmias and chronic heart failure), other than hypertension (p = 0.022, Table 5 ). Both associations were still statistically significant when adjusted for age (p=0.019 and p=0.005, respectively) ( 

Whereas qualitative SARS CoV-2 RT-PCR assays have been widely implemented for the diagnosis of COVID-19 infection, the clinical utility of quantitative SARS CoV-2 RT-PCR for the determination of viral copies remains undetermined.

Studies thus far have shown conflicting evidence in regard to the viral shedding kinetics between mild and severe COVID-19, while there has been no link to clinical outcomes 7, 9 . The goal of this study was to examine whether the diagnostic viral load has any effect or association with known clinical parameters and outcomes.

We showed that diagnostic viral load is higher in non-hospitalized patients and has a significant inverse correlation with duration of symptoms. This inverse relationship of viral load and duration of symptoms was also observed in the hospitalized subgroup, assessed in a univariate and multivariate analysis. Our results corroborate that viral loads peak shortly after symptom onset and support the results of initial Asian cohorts which established that viral load peaks during the pre-symptomatic stage of the disease and slowly declines to become undetectable by day 18-21 7 . Furthermore, we showed that viral loads are inversely correlated with disease severity. We believe that higher viral loads are seen in mild disease rather than severe disease as they reflect the time from onset of infection. These findings are interesting when interpreted within our current knowledge of the natural history of COVID-19. While many COVID-19 patients recover from their initial symptoms over the course of 14-21 days, a sizeable proportion of patients show clinical deterioration to severe disease which usually occurs a week after symptom onset 11 . In our cohort, viral loads detected from nasopharyngeal sampling in patients requiring hospitalization (most of which had severe or critical symptoms) were obtained at a later time point in the disease course. This fact is on par with prior studies demonstrating that longer disease duration is not necessarily associated with a higher viral load but rather a lower viral load 7 . The results also show that patients with mild COVID-19 symptoms may represent the most important "overlooked" source of shedding given the higher viral load. We believe containment strategies can utilize quantitative viral loads to identify that patients with high viral titers.

In the hospital triage setting, the information from the viral load can be utilized to determine which patient would receive a negative pressure room. In the outpatient setting, clinicians can utilize viral load as a quantitative metric to reinforce the importance of self-isolation and face coverings to reduce the risk spreading the Moreover studies thus far have not assessed the relationship between viral load and COVID-19 clinical outcomes. We showed that there was no significant association between viral load and clinical outcomes; including length of stay, oxygen support requirement, or survival. Interestingly, multiple publications have highlighted severe cases of COVID-19 with high morbidity occurring late in the disease process, suggesting that severe symptoms are likely unrelated to high viral titers 11 . Instead, deterioration of patients seems to be related to acute respiratory distress syndrome (ARDS) and multi-system organ failure, related to immunological hyperactivation, characterized by high levels of cytokines, like IL-6 and TNF-α, lymphocyte activation, Thelper 17 differentiation and concomitant severe lymphopenia, most likely due to activation induced cell death 14, 15 . High morbidity and mortality related to COVID-19 appear to be directly linked to this unregulated inflammatory response rather than being caused by high viral load titers per se.

Our study is limited in that the analyzed cohort was predominantly comprised of While it seems that diagnostic viral load has no prognostic utility in terms of outcome prediction, it is an important surrogate epidemiological marker of infectivity notably in mildly symptomatic, non-hospitalized patients. Therefore, our analysis provides the rationale to implement diagnostic viral load in combination with qualitative methods as part of the initial diagnostic armentarium for patients presenting to emergency department with suspicion of COVID19. Nevertheless, while this implementation is most crucial in the asymptomatic or mildly symptomatic patient population, the manual nature of the quantitative assay could limit its large scale integration in the diagnostic laboratory workflow. Automation of quantitative methods could overcome this issue in the future. Tables: Table 1 

Feng Z: Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Group HUSS: Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Temporal dynamics in viral shedding and transmissibility of COVID-19

The early phase of the COVID-19 outbreak in

Viral dynamics in mild and severe cases of COVID-19

The urgency of utilizing COVID-19 biospecimens for research in the heart of the global pandemic

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet

Virological assessment of hospitalized patients with COVID-2019

Clinical progression of patients with COVID-19 in Shanghai

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

COVID-19: Immunology and treatment options

ABSTRACT: